Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4

• Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Taka…

Ab1113 #ACR22 Remibrutinib (LOU064, BTK inhib) in Sjogren's Will there be new Rx for Sjo? T Dorner: 73 pts Ph2 BTK 100mg BID/100 QD/PBO Better ESSDAI at wk 24 (p=0.003) Unstim saliv flow: improved vs PBO, not stat signif Decreased CXCL13 chemokine PROs not improved @RheumNow https://t.co/hJp33JPpHt

DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ

• Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patie…

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) Improvement of ESSDAI, salivary flow and pathologically elevated Ig's Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd

We're used to originator-to-biosimilar switches. Widespread biosim use means we now see biosim-biosim switches (incl as second switch) DANBIO data retention good I see the hallmarks of nocebo still an issue I think we can all agree: ongoing education important #ACR22 @RheumNow https://t.co/6PcMfEEozk

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

Valero et al. Combined biologics in PsA. @RheumNow #ACR22 Abstr1044 https://t.co/7nNf0Ktf0M https://t.co/CIE9BnBFvx

• Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a…

#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO